Marker Start of Second Segment

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer.

First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China.

Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine.

To learn more about the topics in this episode: 
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’
‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO
ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes

This week on "The Top Line," we&rsquo;re covering some of the biggest stories across biopharma before turning to one of the industry&rsquo;s major scientific meetings of the summer.
First, we discuss Vertex&rsquo;s $10 billion acquisition of Crinetics Pharmaceuticals, the company&rsquo;s largest deal to date, and what it says about Vertex&rsquo;s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry&rsquo;s use of clinical trials in China.
Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association&rsquo;s 2026 Scientific Sessions with Fierce Pharma Marketing&rsquo;s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year&rsquo;s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk&rsquo;s new CEO for the first time and the latest from Insulet&rsquo;s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/vertex-acquires-endocrine-disease-specialist-crinetics-10b">Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/us-lawmakers-increase-scrutiny-chinese-trials-industry-fears-huge-distraction-and-expense">As US lawmakers increase scrutiny of Chinese trials, industry fears &lsquo;huge distraction and expense&rsquo;</a></li>
<li><a href="https://www.fiercepharma.com/pharma/if-thats-not-acceleration-i-dont-know-what-novo-nordisk-ceo-doustdar-talks-leadership-new">&lsquo;I&rsquo;m a lot more optimistic today&rsquo;: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/ada-lilly-pulls-back-curtain-impressive-triple-g-efficacy-obesity-and-diabetes-execs-arent">ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes</a></li>
<li><a href="https://www.fiercepharma.com/pharma/ada-amgen-highlights-repatha-benefits-glp-1-pitfalls-amid-aim-become-top-cardiometabolic">ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree</a></li>
<li><a href="https://www.fiercepharma.com/pharma/ada-lilly-widening-its-lead-obesity-race-analyst">With ADA in the books, analyst says Lilly is &lsquo;widening its lead&rsquo; in the obesity race</a></li>
<li><a href="https://www.fiercepharma.com/pharma/ada-novos-wegovy-pill-reaches-new-glp-1-patients-impressive-3m-prescription-milestone">ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/ada-tolerability-not-be-underappreciated-roche-zealands-amylin-obesity-prospect">ADA: Tolerability &lsquo;not to be underappreciated&rsquo; in Roche, Zealand&rsquo;s amylin obesity prospect</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/ada-boehringer-points-survodutides-targeted-weight-loss-tolerability-questions-linger">ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update</a></li>
<li><a href="https://www.fiercepharma.com/pharma/ada-lilly-posts-oral-semaglutide-topping-data-foundayo-speeds-toward-2nd-potential-nod">ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;